Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3603010 | 1.00 | TRPV1 (0.48) | TRPV1MTNR1AMTNR1BPPARGPPARA | |
| SCHEMBL3593344 | 0.82 | TRPV1 (0.51) | TRPV1 | |
| SCHEMBL3593347 | 0.82 | TRPV1 (0.51) | TRPV1 | |
| SCHEMBL3598188 | 0.81 | TRPV1 (0.51) | TRPV1 | |
| SCHEMBL3793148 | 0.81 | TRPV1 (0.51) | TRPV1 | |
| SCHEMBL12802069 | 0.81 | TRPV1 (0.46) | TRPV1 | |
| SCHEMBL8222368 | 0.80 | TRPV1 (0.50) | TRPV1 | |
| SCHEMBL28570841 | 0.80 | TRPV1 (0.56) | TRPV1PPARGPPARATSHR | |
| SCHEMBL8224019 | 0.79 | TRPV1 (0.55) | TRPV1TSHR | |
| SCHEMBL3607179 | 0.78 | PPARG (0.46) | TRPV1MTNR1APPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041665-A1 | N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA, S.A. (ES) | 2010-02-18 | — | — | US | disclosed |
| EP-2057114-A1 | N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA, S.A. (ES) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008015240-A1 | N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA, S.A. (ES) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041665-A1 | N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | PNMT, PSEN1, SNCA | TRPV1 1245/4885MTNR1A 319/4885MTNR1B 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.